Thu, Apr 24, 2025
[Archive]
Volume 32, Issue 154 (September & October 2024)
J Adv Med Biomed Res 2024, 32(154): 323-330 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Irandegani Z, Razavi R, akhondi Meybodi S, Namiranian N, akhondi-Meybodi M. Assessment of the Effectiveness of Direct-Acting Antiviral Therapy in Patients with Hepatitis C: A Follow-Up Analysis in Yazd, Iran. J Adv Med Biomed Res 2024; 32 (154) :323-330
URL: http://journal.zums.ac.ir/article-1-7439-en.html
URL: http://journal.zums.ac.ir/article-1-7439-en.html
Zahra Irandegani1 
, Roghaye Razavi2 , Sanaz Akhondi Meybodi3 , Nasim Namiranian1 , Mohsen Akhondi-Meybodi *4
, Roghaye Razavi2 , Sanaz Akhondi Meybodi3 , Nasim Namiranian1 , Mohsen Akhondi-Meybodi *4
1- Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2- Yazd Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3- Tarbit Moders University, Tehran, Iran
4- Yazd Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran ,akhondei@yahoo.com
2- Yazd Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3- Tarbit Moders University, Tehran, Iran
4- Yazd Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran ,
Abstract: (264 Views)
Background & Objective: Treating hepatitis C as a serious liver disorder is often associated with many problems. Nowadays, Direct-Acting Antiviral (DAA) agents serve as a major remedy in patients with hepatitis C virus (HCV). With regard to the limited information on the effect of using this treatment in different genotypes of the disease in our region, this study seeks to fill the research gap by evaluating the effect of new DAAs on different HCV genotypes in the city of Yazd.
Materials & Methods: Fifty-one patients with different HCV genotypes were treated with Sofosbuvir (SOF) 400 mg + Daclutasvir (DCV) 60 mg and SOF 400 mg + ledipasvir (LDV) 90 regimens. The viral load was assessed in these cases 12 weeks after the end of therapy.
Results: In this study, the mean age of patients was 50.04 (± 10.53) years. Among the participants, the most observed genotype was type 1 (54.8%). The most current risk factor was drug use (47%). The analysis revealed that 78% of the patients had a sustained virological response (SVR). SVR rate in HCV was obtained as follows: genotype 1 (77.3%), genotype 2 (66.7%), genotype 3 (87.5%), genotype 4 (100%) and genotype 1+3 (75%).
Conclusion: Overall, the application of DAAs has no side effects and induces relatively good therapeutic responses. However, the responses to the drugs used in this study have been lower than those reported in similar studies worldwide.
Materials & Methods: Fifty-one patients with different HCV genotypes were treated with Sofosbuvir (SOF) 400 mg + Daclutasvir (DCV) 60 mg and SOF 400 mg + ledipasvir (LDV) 90 regimens. The viral load was assessed in these cases 12 weeks after the end of therapy.
Results: In this study, the mean age of patients was 50.04 (± 10.53) years. Among the participants, the most observed genotype was type 1 (54.8%). The most current risk factor was drug use (47%). The analysis revealed that 78% of the patients had a sustained virological response (SVR). SVR rate in HCV was obtained as follows: genotype 1 (77.3%), genotype 2 (66.7%), genotype 3 (87.5%), genotype 4 (100%) and genotype 1+3 (75%).
Conclusion: Overall, the application of DAAs has no side effects and induces relatively good therapeutic responses. However, the responses to the drugs used in this study have been lower than those reported in similar studies worldwide.
Type of Study: Original Research Article |
Subject:
Pharmacology
Received: 2024/02/3 | Accepted: 2024/12/11 | Published: 2024/10/19
Received: 2024/02/3 | Accepted: 2024/12/11 | Published: 2024/10/19
References
1. https://www.who.int/health-topics/hepatitis#tab=tab_1.
2. Bradley C, Scott R, Cox E, Palaniyappan N, Thomson B, Ryder S, et al. Short-term changes observed in multiparametric liver MRI following therapy with direct-acting antivirals in chronic hepatitis C virus patients. Europ Radiol. 2019;29(6):3100-7. [DOI:10.1007/s00330-018-5788-1] [PMID] [PMCID]
3. Pomper GJ, Wu Y, Snyder EL. Risks of transfusion-transmitted infections: 2003. Curr Opin Hematol. 2003;10(6):412-8. [DOI:10.1097/00062752-200311000-00003] [PMID]
4. Dienstag JL. Sexual and perinatal transmission of hepatitis C. Hepatology. 1997;26(S3):66S-70S. [DOI:10.1002/hep.510260712] [PMID]
5. Ohto H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C, et al. Transmission of hepatitis C virus from mothers to infants. New Eng J Med. 1994;330(11):744-50. [DOI:10.1056/NEJM199403173301103] [PMID]
6. Bronowicki J-P, Venard V, Botte C, Monhoven N, Gastin I, Choné L, et al. Patient-to-patient transmission of hepatitis C virus during colonoscopy. New Eng J Med. 1997;337(4):237-40. [DOI:10.1056/NEJM199707243370404] [PMID]
7. Haley RW, Fischer RP. Commercial tattooing as a potentially important source of hepatitis C infection: clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine. 2001;80(2):134-51. [DOI:10.1097/00005792-200103000-00006] [PMID]
8. Ferreira VL, Borba HHL, Wiens A, Pedroso MLA, Radunz VFdC, Ivantes CAP, et al. Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil. Brazil J Infect Dis. 2018;22(3):186-92. [DOI:10.1016/j.bjid.2018.04.003] [PMID] [PMCID]
9. Kwo PY, Puenpatom A, Zhang Z, Hui SL, Kelley AA, Muschi D. Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis. PloS one. 2019;14(8):e0218759. [DOI:10.1371/journal.pone.0218759] [PMID] [PMCID]
10. Alavinejad P, Hajiani E, Hashemi SJ, Shayesteh AA, Ebadi Borna K, Nasooti MA, et al. Hepatitis C virus treatment with sofosbuvir plus ribavirin regimen in Khuzestan province. Jundishapur J Chron Dis Care. 2018;7(4). [DOI:10.5812/jjcdc.81105]
11. Iacob S, Cerban R, Pietrareanu C, Ester C, Iacob R, Gheorghe C, et al. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation. J Gastrointestin Liver Dis. 2018;27(2):139-44. [DOI:10.15403/jgld.2014.1121.272.100] [PMID]
12. Holzmann I, Tovo CV, Minmé R, Leal MP, Kliemann MP, Ubirajara C, et al. Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil. Brazil J Infect Dis. 2018;22(4):317-22. [DOI:10.1016/j.bjid.2018.06.004] [PMID] [PMCID]
13. Pan CQ, Gayam V, Rabinovich C, Normatov M, Fidman B, Wang D, et al. Efficacy of direct‐acting antivirals for chronic hepatitis C in a large cohort of older adults in the United States. J Am Geriat Soc. 2020;68(2):379-87. [DOI:10.1111/jgs.16206] [PMID]
14. Ji D, Chen GF, Wang C, Wang YD, Shao Q, Li B, et al. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients. Hepatol Int. 2016;10(5):789-98. [DOI:10.1007/s12072-016-9755-0] [PMID]
15. Sette-Jr H, Cheinquer H, Wolff FH, de Araujo A, Coelho-Borges S, Soares SR, et al. Treatment of chronic HCV infection with the new direct acting antivirals (DAA): first report of a real world experience in Southern Brazil. Ann Hepatol. 2017;16(5):727-33. [DOI:10.5604/01.3001.0010.2717] [PMID]
16. Benhammou JN, Dong TS, May FP, Kawamoto J, Dixit R, Jackson S, et al. Race affects SVR 12 in a large and ethnically diverse hepatitis C‐infected patient population following treatment with direct‐acting antivirals: Analysis of a single‐center Department of Veterans Affairs cohort. Pharmacol Res Perspect. 2018;6(2):e00379. [DOI:10.1002/prp2.379] [PMID] [PMCID]
17. Bachofner J, Valli PV, Bergamin I, Kröger A, Künzler P, Baserga A, et al. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland. Swiss Med Week. 2018;148:w14560. [DOI:10.4414/smw.2018.14560] []
18. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New Eng J Med. 2014;370(3):211-21. [DOI:10.1056/NEJMoa1306218] [PMID]
19. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New Eng J Med. 2014;370(20):1879-88. [DOI:10.1056/NEJMoa1402355] [PMID]
20. Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64(6):1224-31. [DOI:10.1016/j.jhep.2016.01.029] [PMID]
21. Serdar CC, Cihan M, Yücel D, Serdar MA. Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies. Biochem Med. 2021;31(1):27-53. [DOI:10.11613/BM.2021.010502] [PMID] [PMCID]
22. Demirturk N, Aygen B, Celik I, Mistik R, Akhan S, Barut S, et al. Real-world data from Turkey: Is sofosbuvir/ledipasvir with or without ribavirin treatment for chronic hepatitis C really effective? Turk J Gastroenterol. 2021;32(2):155-64. [DOI:10.5152/tjg.2020.19569] [PMID] [PMCID]
23. Hariri S, Alavi M, Roshandel G, Mohammadi Z, Fazel A, Amiriani T, et al. An intervention to increase hepatitis C virus diagnosis and treatment uptake among people in custody in Iran. Int J Drug Policy. 2021;95:103269. [DOI:10.1016/j.drugpo.2021.103269] [PMID]
24. Moradi G, Jafari S, Zarei B, Mahboobi M, Zavareh FA, Molaeipoor L, et al. Prevalence and risk factors for hepatitis B and hepatitis C exposure in Iranian prisoners: a national study in 2016. Hepatitis Monthly. 2019;19(7). [DOI:10.5812/hepatmon.91129]
25. Younossi ZM, Stepanova M, Henry L, Han KH, Ahn SH, Lim YS, et al. Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health‐related quality of life in East Asian patients with hepatitis C virus infection. J Viral Hepatit. 2018;25(12):1429-37. [DOI:10.1111/jvh.12965] [PMID]
26. Sharafi H, Behnava B, Azizi-Saraji A, Namvar A, Anvar A, Salimi S, et al. Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders. Virol J. 2021;18(1):1-10. [DOI:10.1186/s12985-021-01659-0] [PMID] [PMCID]
27. Yang TH, Fang YJ, Hsu SJ, Lee JY, Chiu MC, Yu JJ, et al. editors. Microelimination of chronic hepatitis C by universal screening plus direct-acting antivirals for incarcerated persons in Taiwan. Open Forum Infect Dis; 2020: Oxford University Press US. [DOI:10.1093/ofid/ofaa301] [PMID] [PMCID]
28. Hill A, Khwairakpam G, Wang J, Golovin S, Dragunova J, Smith R, et al. High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C. J Virus Eradicat. 2017;3(4):200-3. [DOI:10.1016/S2055-6640(20)30324-1] [PMID]
29. Nainan OV, Alter MJ, Kruszon-Moran D, Gao F-X, Xia G, McQuillan G, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterol. 2006;131(2):478-84. [DOI:10.1053/j.gastro.2006.06.007] [PMID]
30. Samimi‐Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L. Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol. 2004;74(2):246-52. [DOI:10.1002/jmv.20170] [PMID]
31. Stedman C, Hyland R, Ding X, Pang P, McHutchison J, Gane E. Once daily ledipasvir/sofosbuvir fixed‐dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia. 2016;22(2):214-7. [DOI:10.1111/hae.12791] [PMID]
32. Xiao H, Chen J, Wang J, Li J, Yang F, Lu H. Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection. Medicine. 2019;98(30). [DOI:10.1097/MD.0000000000016524] [PMID] [PMCID]
33. Lee HW, Yoo KY, Won JW, Kim HJ. Direct acting antiviral agents in Korean patients with chronic hepatitis C and hemophilia who are treatment-naïve or treatment-experienced. Gut Liver. 2017;11(5):721. [DOI:10.5009/gnl17209] [PMID] [PMCID]
34. Nagao A, Hanabusa H. Brief report: the impact of ledipasvir/sofosbuvir on HIV-positive and HIV-negative Japanese hemophilia patients with 1, 4, and mixed-genotype HCV. J Acq Immune Def Syndrom. 2017;74(4):418-22. [DOI:10.1097/QAI.0000000000001271] [PMID]
35. Guedes TP, Garrido M, Morais S, Pedroto I. High rate of SVR with DAA in haemophiliacs with HCV infection: three decades of follow-up of a Portuguese single-centre cohort. Liver Int. 2020;40(7):1783-4. [DOI:10.1111/liv.14413] [PMID]
36. Merat S, Sharifi AH, Haj-Sheykholeslami A, Poustchi H, Fattahi B, Nateghi-Baygi A, et al. The efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3. Hepatitis Monthly. 2017;17(1):4. [DOI:10.5812/hepatmon.44564]
37. Sharafi H, Nikbin M, Alavian SH, Behnava B, Alavian SM. Efficacy and safety of generic sofosbuvir/ledipasvir fixed-dose combination in Iranian patients with chronic hepatitis C virus infection. Hepatit Month. 2017;17(6). [DOI:10.5812/hepatmon.12216]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
